Two-Year Analysis of CARTITUDE-1 Shows Early, Durable and Deepening Responses of Ciltacabtagene Autoleucel (cilta-cel) in Heavily Pretreated Patients with Multiple Myeloma

Go back to Two-Year Analysis of CARTITUDE-1 Shows Early, Durable and Deepening Responses of Ciltacabtagene Autoleucel (cilta-cel) in Heavily Pretreated Patients with Multiple Myeloma
(NASDAQ: LEGN) Delayed: 17.88 +0.08 (0.45%)
Previous Close $17.80    52 Week High $ 
Open $17.61    52 Week Low $ 
Day High $18.28    P/E N/A 
Day Low $17.56    EPS $ 
Volume 2,458,901